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Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from 
seizures despite antiepileptic drug (AED) treatment. Although the advent of newer AEDs offers hope for better 
treatment, there is a need to compare the efficacy of each new AED in adults with both drug-resistant epilepsy 
and learning disabilities. 
This retrospective casenote study involves the analysis of the outcome for those adults with learning disabilities 
treated with either vigabatrin, lamotrigine or gabapentin. The information obtained from the casenote analysis was 
used to both compare the efficacies of the three drugs and also the side-effects and drop-out rates, including 
reasons for drop-out. The total number of patients involved was 51 who underwent 71 treatment episodes. All 
three AEDs had similar efficacies. Although vigabatrin was found to be associated with a higher incidence of 
behaviour problems, behaviour problems occurred with the other drugs as well. Lamotrigine caused increased 
seizures in 24% of patients, especially when prescribed at a higher dose. Gabapentin appeared to be associated 
with fewer serious side-effects. 
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INTRODUCTION 
Epilepsy is common among the learning disabled 
population, especially those with severe or 
profound degree, of learning disabilities’. It is 
estimated that in the community there are at least 
1600 people per million with both epilepsy and 
learning disability’ and up to 44% of these people 
are in touch with secondary services. A survey of 
all the severely learning disabled children origi- 
nating from the London borough of Camberwell” 
showed that: one third of these children had 
experienced seizures at some time and one fifth 
had at least one seizure in the year before the 
enquiry; the risk of seizure disorder increases 
with the severity of learning disability; where 
postnatal injury is a factor in causing a severe 
degree of learning disabilities, epilepsy is virtually 
inevitable; for many, epilepsy may persist well 
into their adult life; the prevalence of epilepsy 
appears to be more common amongst boys when 
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compared to that of girls. These findings were 
confirmed by Richardson ef alJ. 
A substantial proportion of patients with 
learning disabilities and epilepsy continue to 
suffer from poorly-controlled seizures despite the 
use of two or more antiepileptic drugs (AEDs)‘. 
The situation is further complicated by the 
complex interactions between the multiple needs 
of these individuals. Many suffering from drug- 
resistant epilepsy not only suffer from severe or 
profound degrees of learning disabilities but also 
have associated secondary handicaps including 
increased susceptibilty to physical illness, con- 
stipation and infectionh. They are frequently on 
more than one AED and both drug interactions 
and side-effects are problematic. In addition 
there are often difficulties in assessing drug 
side-effects, including the effect of the medication 
on cognitive functioning, because of concurrent 
cognitive impairment. 
Many adults with learning disabilities and 
epilepsy suffer from more than one seizure type 
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although the nature of the seizures may be similar 
to those suffered by non-learning disabled epilep- 
tics. In addition there may also be the problem of 
an associated behaviour disorder/psychiatric 
disorder’,*. It is possible to classify the seizure 
disorders occurring in these individuals by its 
phenomenology although history may need to be 
supplemented by EEG studies’. In one large 
study a precise diagnosis could only be deter- 
mined in 34% of all people suffering from 
epilepsy who attended a general practice clinic”. 
EEG studies can occasionally present with 
difficulties in some of the patients belonging to 
this group, especially because of the lack of 
understanding and the lack of co-operation in 
going through such a procedure. Similar problems 
might be encountered in further investigations 
such as CT head scan or MRI scan. It is 
acknowledged that in the epileptic population 
with learning disabilities a substantial proportion 
of patients also experience pseudo-seizures. 
However, the extent of this problem and the 
prevalence of it is, as yet, unclear compared to 
that of the general population. 
The drug treatment of epilepsy in people with 
learning disabilities has previously been confined 
to the use of AEDs such as sodium valproate, 
carbamazepine, phenytoin or benzodiazepines 
including clobazam and clonazepam. The seizure 
disorder in the majority of the patients is well 
controlled with the use of one AED or, at best, a 
combination of two. However, a substantial 
minority of patients do continue to suffer from 
seizures despite the use of two or more drugs and 
it is this group of patients who are likely to 
benefit from the use of a newer AED. Until the 
recent introduction of three new AEDs (vigabat- 
rin, lamotrigine and gabapentin) the treatment of 
poorly controlled epilepsy has been limited to 
adjusting doses of a handful of older AEDs. 
Reducing the number of AEDs taken by in- 
dividual patients tends to reduce adverse events 
but can lead to an increase in seizure frequency”. 
The introduction of vigabatrin, lamotrigine and 
gabapentin has increased the choice of this area 
of drug treatment but has it increased the 
likelihood of a reduction in seizures? Very few 
studies have been carried out on patients with 
learning disabilities suffering from poorly con- 
trolled epilepsy. In a study of the antiepileptic 
efficacy of vigabatrin’* in 36 patients with 
learning disabilities and drug-resistant epilepsy, 
43% of the patients with seizures of partial onset 
and 33% of the patients with primary generalized 
seizures showed more than 50% reduction in 
seizure frequency during a 7-seven month 
follow-up period. Twenty-two adult patients with 
learning disabilities were treated in an open trial 
with vigabatrin I3 Forty-five per cent showed a . 
reduction in seizure frequency of more than 50%. 
Adverse events were reported in 20 of the 22 
patients during the 64 week study period, the 
most frequently reported adverse events being 
sedation, aggression, agitation and ataxia. Other 
clinical trials that have included patients with 
learning disabilities were a study of lamotrigine in 
120 children14, 62% of whom suffered from 
learning disabilities, and a three-cohort study of 
vigabatrin one cohort of which was 36 learning 
disabled patients with severe epilepsy”. Both 
clinical trials demonstrated similar efficacy to 
those by others’2.‘3. 
Our study is a naturalistic study. We reviewed 
the first 51 patients prescribed vigabatrin, lamot- 
rigine and gabapentin. All were adults with 
learning disabilities suffering from refractory 
epilepsy, the aim being to compare the efficacies, 
adverse events and drop-out rates for all three 
drugs. 
MATERIALS AND METHODS 
The case lists of the four consultant psychiatrists 
employed by the Glenfrith Division of Fosse 
Health Trust were examined in order to identify 
those patients prescribed either vigabatrin, 
lamotrigine or gabapentin. For each patient 
prescribed any of the three new AEDs within the 
period 1991-1995, a retrospective casenote 
analysis was undertaken. Information was 
gathered and comparisons were made between 
the three treatment groups of vigabatrin, 
lamotrigine and gabapentin regarding age, sex, 
residence, degree of learning disabilities, cause of 
primary handicap, age of onset of epilepsy, AEDs 
prescribed prior to prescribing the new drugs, 
current AEDs, seizure frequency prior to and 
after add-on therapy, any side-effects reported, 
and drop-out rates including reasons for drop- 
out. The data was collected and analysed using 
SPSS. 
RESULTS 
The study of 51 casenotes revealed 71 occasions, 
during the previous 4 years, when patients were 
prescribed either vigabatrin, lamotrigine or gaba- 
pentin. As some patients were treated with more 
than one newer AED, the calculations were 
made in terms of treatment episodes. Twenty- 
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three treatment episodes were identified with 
vigabatrin, 25 with lamotrigine and 23 with 
gabapentin. In the vigabatrin group 12 patients 
were treated with vigabatrin alone. Similarly, 10 
patients were treated with lamotrigine alone in 
the lamotrigine group. In the gabapentin group 
there were 10 individuals who were treated with 
gabapentin alone. There were altogether three 
individuals who were tried with all three newer 
AEDs in succession and there were 16 patients 
who were treated with two of the newer drugs out 
of three. Twenty-eight patients were male and 23 
female. The mean age for males was 39 years 
(range, 21-54 years) and for females 38 years 
(range, 20-66 years). The age and sex distribution 
between the three groups were found to be very 
similar. The mean age for patients treated with 
vigabatrin, lamotrigine and gabapentin was noted 
to be 39 f 10 years, 36 f 9 years and 37 f 9 years, 
respectively. 
Epilepsy had been diagnosed in most patients 
in childhood and all patients had other disabilities 
in addition to epilepsy. The age of onset of 
epilepsy ranged from 6 weeks to 49 years, with 
96% suffering from epilepsy before the age of 5 
years. 
Despite suffering from refractory epilepsy, 
most patients were living in the community: 23 
(45%) were living with parents or relatives, 11 
(22%) were living in hostels and the remainder 
lived in hospital. 
The causes of the learning disabilities were 
known or suspected in 50% of the patients and 
included conditions such as cerebral palsy, 
meningitis, congenital brain malformations and 
perinatal brain damage. Cerebral palsy and 
meningitis/encephalitis appeared to be the most 
common causes of learning disabilities. 
Table 1: The primary causes of learning disabilities in 
patients treated with vigabatrin, lamotrigine and 
oabaoentin 
Primary diagnosis Vigabatrin Lamotrigine Gabapentin 
Cerebral palsy 
Encephalitis/ 
meningitis 
Birth trauma 
Neonatal jaundice 
Neonatal diabetes 
Autism 
Down syndrome 
Sturge Webber 
syndrome 
Lafora body disease 
Epiloia 
Unknown 
5 2 4 
6 4 
2 
0 
0 
0 
1 
II 
3 
0 
0 
0 
0 
9 
Although the distribution of the causes of 
learning disability were similar for those treated 
with either vigabatrin, lamotrigine or gabapentin, 
there were some differences between the 
treatment groups (see Table 1). 
An assessment of the degree of learning 
disability was carried out. The patients spanned 
all levels of ability (10 mild, 15 moderate, 18 
severe and eight profoundly learning disabled). 
Although more of those with mild learning 
disabilities and fewer of those with profound 
learning disability were female, the distribution of 
degree of learning disabilities by gender was 
similar. Although the distribution of degree of 
learning disabilities was found to be broadly 
similar in the three treatment groups, more 
patients with severe learning disabilities received 
lamotrigine and gabapentin compared to that of 
vigabatrin (see Table 2). - 
The main seizure type suffered by the patients 
was noted to be primary generalized (n = 37, 
73%). The remainder suffered from complex 
partial seizures and partial seizures, with or 
without secondary generalization. Twenty-eight 
patients (61%) suffered from one seizure type 
with 15 (29%) suffering from two seizure types 
and eight (10%) suffering from three or more 
seizure types. There was little difference between 
the type of seizures suffered by the patients in 
three treatment groups. 
The seizure frequency prior to treatment with 
newer AEDs was found to be very similar in all 
the three treatment groups with a median seizure 
frequency of 5-10 seizures per month and the 
range of the frequency being a minimum of l-5 
seizures per month, maximum up to more than 30 
seizures per month. 
Twenty-five percent of the patients prior to 
treatment with newer AEDs were prescribed only 
one AED and 50% prescribed two AEDs, with 
the remaining 25% of the patients receiving three 
AEDs or more. Most patients had previously 
received carbamazepine or sodium valproate with 
the individual drug use of carbamazepine 39, 
sodium valproate 26, phenytoin 13, clonazepam 
Table 2: The degree of learning disabilities for patients 
treated with either vigabatrin, lamotrigine or gabapentin 
Degree of Vigabatrin Lamotrigine Gabapentin 
learning 
disabilities 
Mild 7 (30%) 2 (8%) 5 (22%) 
Moderate 7 (30%) 8 (32%) 5 (22%) 
Severe 6 (27%) 11 (44%) 9 (39%) 
Profound 3 (13%) 4 (16%) 4 (17%) 
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12, phenobarbitone 7, clobazam 4, primidone 2, 
ethosuximide 1 patient, respectively. The high 
prescribing rate for drugs such as phenytoin, 
phenobarbitone and primidone is more related to 
the refractory nature of the epilepsy in these cases 
than their general use. There was little difference 
between the treatment groups in respect of the 
number of AEDs they had been taking prior to 
treatment with the newer AEDs. 
Table 4: The relative efficacy of the new AEDs 
>50% seizure 
reduction 
Vigabatrin Lamotrigine Gabapentin 
(n =23) (n =25) (n =23) 
10(43%) 9(36%) 13(56%) 
The doses and duration of treatment with the 
three new AEDs are provided in Table 3, 
whereas Table 4 shows the relative efficacy of the 
three newer drugs in the reduction of seizures. All 
three drugs appear to have similar efficacies, with 
36% to 56% of patients benefiting from a seizure 
reduction of more than 50%. It was interesting to 
note that 26% of patients on vigabatrin became 
seizure-free compared to only 4% for gabapentin 
and none for lamotrigine. 
Seizure-free 6(26%) 0 (0%) 1 (4%) 
Side-effects 9 (39%) 7(28%) 6(26%) 
Increased seizures 2 (8%) 6 (24%) 0 (0%) 
N.B. Some patients received treatment with more than one 
newer AED. 
DISCUSSION 
Although more side-effects were reported by 
patients on vigabatrin rather than lamotrigine and 
gabapentin, this was not statistically significant 
(P = 0.58). It was surprising to note that 24% of 
patients on lamotrigine suffered from increased 
seizures compared to 8% for vigabatrin and none 
in the gabapentin group. 
When discontinuation of the newer AED 
occurred it was either due to side-effects, lack of 
effect or increased seizures. Table 5 examines the 
reason for discontinuation. All three drugs 
appeared to be very similar in the reasons for 
discontinuation. Although fewer patients on 
gabapentin discontinued due to side-effects, this 
is not statistically significant. 
The problem in carrying out a clinical drug trial 
in the field of learning disabilities is well known 
and includes many ethical and consent issues. 
There is also the associated problem of high 
extent of polypharmacy and other co-existing 
physical and mental health problems which tend 
to exclude many patients from the clinical drug 
trials. This study has the strength of being 
naturalistic and therefore reflected what hap- 
pened in real clinical practice as there were no 
exclusion criteria. However, it has its limitations 
of being a retrospective casenote analysis and 
therefore caution should be exercised in drawing 
definitive conclusions. 
Table 6 shows the prevalence of reported 
side-effects with each drug. In the vigabatrin 
group increased behaviour problems was the 
most common side-effect encountered. However, 
two patients in the lamotrigine group and one 
patient in the gabapentin group suffered similar 
problems. Three patients on lamotrigine suffered 
rashes which did not occur with the other two 
drugs. Drowsiness and unsteady gait were the 
main side-effects reported with gabapentin. 
Patients who continue to suffer from seizures 
despite adequate drug treatment remain a chall- 
enging group for the medical profession. The 
introduction of new AEDs offers hope for 
patients with epilepsy who remain refractory to 
medical treatment. This study suggests that all the 
three new AEDs (vigabatrin, lamotrigine and 
gabapentin) can be effective add-on treatment for 
poorly controlled epilepsy in patients with 
learning disabilities but that only 30-50% of the 
patients are likely to benefit from such treatment. 
It is clear that in this study the clinicians did not 
prescribe the newer AEDs within their data sheet 
indication and the reasons for choosing one 
particular new AED in each particular case 
appeared to have been determined by chronolog- 
Table 3: The doses and duration of treatment with vigabatrin, lamotrogine and gabapentin 
Vigabatrin Lamotrigine Gabapentin 
Median dose 
Maximum dose 
Minimum dose 
Standard deviation dose 
Median duration of treatment 
Maximum duration of treatment 
Minimum duration of treatment 
Standard duration of treatment 
2000 mg 
4000 mg 
1000 mg 
806 mg 
24 months 
60 months 
1 month 
17 months 
150 mg 
500 mg 
1OOmg 
129mg 
18 months 
36 months 
1 month 
13 months 
1200 mg 
2400 mg 
600 mg 
400 mg 
12 months 
36 months 
1 month 
105 months 
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Table 5: Reasons for discontinuation of vigabatrin. 
lamotrigine and gabapentin drug treatment 
Drugs Due to Due to lack Total 
side-effects of effect or 
increased 
seizures 
Vigabatrin 8 (35%) 4 (17%) 12 (52%) 
(n = 23) 
Lamotrigine 7 (28%) 7 (28%) I4 (56%) 
(II = 25) 
Gabapentin 4 (17%) 7 (30%) II (47%) 
(II = 23) 
ical availability of the newer drugs rather than 
anything else; nevertheless, there are some 
indications that some of the newer drugs, e.g. 
lamotrigine and gabapentin, may be effective in 
controlling refractory primary generalized 
seizures as well. In this study gabapentin was the 
most successful AED in achieving a more than 
50% seizure reduction despite the fact that the 
dosage used was only up to the recommended 
limit at that time. Increasingly, more evidence is 
coming out that gabapentin is likely to achieve 
better seizure control at a much higher dose level 
than that which was previously recommended. 
However, it was interesting to note that 26% of 
patients with vigabatrin became seizure-free, 
compared to only 4% of patients with gabapentin 
and none with lamotrigine. although overall all 
three drugs were similar in their performance. 
appeared to be the drug with fewer interactional 
problems and better side-effect profile when 
compared to the other two groups of drugs, the 
small numbers involved in this study made these 
findings difficult to generalize. The overall dis- 
continuation rates in three different groups 
appear to be very similar, with the lowest rate 
being noted in the gabapentin group. However, 
this finding could be challenged because patients 
are likely to have received gabapentin for a 
shorter period of time as it is the most recently 
available of the three drugs. Recent reports, 
however, have suggested that gabapentin, if well 
tolerated, can be used in a much higher dose than 
the recommended at present and at the higher 
dose range it is likely to achieve more benefit. 
The problem of increased seizures with drug 
treatment with newer AEDs has not been 
researched adequately and it was striking to note 
that 24% of patients on lamotrigine suffered from 
increased seizures. This development of increase 
of seizures appeared to be linked with the use of a 
higher dose of lamotrigine. None of the patients 
on gabapentin suffered from any increased 
seizures.. 
The adverse events noted for each drug are 
very similar to those of previous reviews”‘. 
However, it was interesting to note that increased 
behaviour problems (though most frequently 
encountered with vigabatrin) were not confined 
to that drug alone. Although gabapentin 
The study identified several specific issues 
related to epilepsy in the learning disabled 
population. The interactions between physical, 
social and psychological problems in individuals 
suffering from epilepsy and learning disability are 
complex and their impact on the patient and 
his/her carers can influence the outcome of any 
medical interventions. Moreover, many learning- 
disabled patients suffer from compromised 
renal/hepatic functions and may also suffer from 
increased susceptibility to infections, constipation 
etc. which can influence AED therapy and 
effective seizure control adversely. There is also 
an increased prevalence of polypharmacy and 
associated problems of drug interactions and it is 
worthwhile to bear in mind that many patients are 
on additional psychotropic medication for their 
associated behaviour problems or psychiatric 
disorders which are likely to influence their 
seizure threshold. Any impact of AED therapy 
on an individual has to be assessed globally. 
including the impact of the medication on the 
individual’s cognitive functions. The majority of 
the patients with learning disabilities have already 
somewhat compromised cognitive functions and 
any further deterioration of the cognitive func- 
tions can cause a dramatic deterioration in their 
quality of life. Caring for individuals with learning 
disabilities and epilepsy for a life time can be 
quite stressful for the carers and it is imperative 
Table 6: Reported side-effects 
Vieabatrin 
Behaviour problems 
Drowsiness 
lncrcased myoclonic jerks 
Lamotrigine Gabapentine 
5 Rash 2 Unsteady gait 2 
3 Behaviour problems 2 Drowsiness 2 
I Steven Johnson Initial insomnia I 
Syndrome I Behaviour problems I 
Persistent vomitin I 
Unsteady cgait I 
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that the clinicians dealing with such individuals 
should pay due attention to carer stress and the 
associated family dynamics. Furthermore, some 
individuals suffer from progressive neurodegene- 
rative conditions, for example Rett’s Syndrome, 
where heroic attempts to control and reduce the 
seizure frequency can lead to a disastrous impact 
on the patient’s quality of life and thereby cause 
more distress. In general it is important to bear in 
mind that in dealing with a patient with learning 
disability suffering from refractory epilepsy, a 
global assessment is imperative and any interven- 
tion plan is to be discussed in detail including the 
associated risks and benefits with the carers and 
individual concerned, where possible. When a 
newer AED treatment is initiated, clinicians 
should maintain regular contact with the 
family/carers and a slow, gradual, introduction of 
the newer drug is highly preferable than the 
introduction plan suggested by most of the data 
sheets. This is helpful, not only in avoiding 
side-effects, but also in avoiding any compliance 
problems. In assessing patients with epilepsy, the 
primary factor has conventionally been the 
reduction or abolition of seizures. However, this 
represents a rather simplistic approach. Seizure 
frequency may vary spontaneously and the 
seizure number does not wholly reflect disability 
since the severity of the seizure is ignored and 
associated psychological issues are not addressed. 
In addition, social aspects should ideally be taken 
into account. Any adverse event, when it arises, 
can cause distress in the individual concerned and 
also for the carers and opportunities should exist 
for them to contact the clinician immediately for 
advice and support. The drop-out rates can be 
minimized by such a carefully laid out plan. 
which enhance independence are needed to be 
taken into account when considering the impact 
of any drug treatment of epilepsy in individuals 
with learning disabilities. A long-term prospec- 
tive study using the newer drugs in an open-ended 
trial in adults with learning disabilities suffering 
from refractory epilepsy will clarify these issues 
and might help us to identify the likely responders 
and also to select specific newer AEDs for 
individual patients. 
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